Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT03973138
- Locations
- 🇨🇳
Kunbei Lai, Guangzhou, Guangdong, China
Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Ophthalmica Eye Institute
- Target Recruit Count
- 16
- Registration Number
- NCT03944070
- Locations
- 🇬🇷
Ophthalmica Eye Institute, Thessaloníki, Kalamaria, Greece
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Bay Area Retina Associates
- Target Recruit Count
- 32
- Registration Number
- NCT03832179
- Locations
- 🇺🇸
Bay Area Retina Associates, Walnut Creek, California, United States
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
- Conditions
- Interventions
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT03725501
- Locations
- 🇰🇷
AngioLab, Inc., Daejeon, Daejeon Gwangyeogsi, Korea, Republic of
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Marsden Eye Specialists
- Target Recruit Count
- 160
- Registration Number
- NCT03495765
- Locations
- 🇦🇺
Marsden Eye Specialists, Paramatta, New South Wales, Australia
Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2018-03-02
- Target Recruit Count
- 118
- Registration Number
- NCT03452657
- Locations
- 🇨🇳
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
🇨🇳Shanghai ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
🇨🇳Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
Ziv-aflibercept Efficacy in Better Regulating AMD
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Kapil Kapoor
- Target Recruit Count
- 62
- Registration Number
- NCT03423823
- Locations
- 🇺🇸
Wagner Macula & Retina Center, Virginia Beach, Virginia, United States
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Vista Klinik
- Target Recruit Count
- 30
- Registration Number
- NCT03393767
- Locations
- 🇨🇭
Vista Klinik, Binningen, Switzerland
Refractive Error and Biometry in Retinopathy of Prematurity
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- San Ni Chen
- Target Recruit Count
- 35
- Registration Number
- NCT03334513
Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03054766
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.